Hypofractionated radiotherapy with concurrent chemotherapy with weekly cisplatin in locally advanced relatively radioresistent subsites of head and neck cancers

  • Отримано 15.09.2022
  • Доопрацьовано 25.11.2022
  • Прийнято 27.12.2022
  • 874 Перегляди
  • Взято з Vol. 8, No. 2, 2022
  • Сторінки 24-33

Background. Locoregionally advanced head and neck cancers are more aggressive and locoregional failure rate after conventional radiotherapy is high. Objective. The aim of the study is to assess the tumor response and toxicities of hypofractionated radiation therapy  with  concurrent  chemotherapy  in  treatment  of  four  relatively  radioresistent  tumor  sites  of  head  and  neck. Methods. A prospective randomised control trial was conducted in 27 head and neck cancer patients. All patients were treated with hypofractionated radiotherapy at 250cGy/fraction once daily to a maximum of 62.5Gy in 25 fractions with concurrent cisplatin 30 mg/m2. Data were evaluated with SPSS version 21.0 for Windows with p-value <0.05. Results. Complete and partial responses were achieved in 15 (57.7%) and 8 (30.8%) patients respectively with an overall response rate of 88.5% and three patients having stable disease. Grade 3 and 4 acute mucositis was experienced by 17 patients (65.4%) and seven patients (27%), respectively. Grade 3 dysphagia was found in 21 patients (80.7%) and grade 3 and 4 skin reactions – in 11 and 2 patients, respectively. Most patients had manageable acute toxicities. Most of the late complications were of grade 2 and 3. The median time to locoregional recurrence was 12 months and one year progression-free survival attained by 61.5% patients. Conclusion. Treatment with hypofractionated radiotherapy with concurrent cisplatin appears feasible and safe and is associated with a good response rate. Although grade 3 and 4 toxicities were comparatively high but it was manageable. Late toxicities were within tolerable levels gia was found in 21 patients (80.7%) and grade 3 and 4 skin reactions – in 11 and 2 patients, respectively. Most patients had manageable acute toxicities. Most of the late complicons were of grade 2 and 3. The median time to locoregional recurrence was 12 months and one year progression-free survival attained by 61.5% patients. Conclu

head and neck cancer; hypofractionated; radioresistent; response; mucositis

https://doi.org/10.11603/ijmmr.2413-6077.2022.2.13118

[1] Semple C, Parahoo K, Norman A, McCaughanE, Humphris G, Mills M. Psychosocial interventions for patients with  head  and  neck  cancer.  Cochrane  Database Syst Rev 2013; 7: CD009441. doi: 10.1002/14651858.CD009441.pub2.

[2] Bray  F,  Ferlay  J,  Soerjomataram  I,  Siegel  RL,  Torre LA, Jemal A. Global cancer statistics 2018:GLOBOCAN estimates of mortality worldwide for 36 cancers  in  185  countries.  CA  Cancer  J  Clin  2018;  68(6):394­424. doi: 10.3322/caac.21492.

[3] Report of National Cancer Registry Programme (ICMR­NCDIR), Bengaluru, India 2020. Available at: https://www.ncdirindia.org/All_Reports/Report_2020/default.aspx. Accessed on 26.12.2022.

[4] Mendenhall  WM,  Werning  JW,  Pfister  DG.  Cancer of the head and neck. In: DeVita VT, Hellman S, Rosenberg SA, editors. Cancer: Principals and practice of Oncology. 10th ed. Philadelphia: Wolters Kluwer; 2015. p. 422-24. 

[5] Agarwal JP, Nemade B, Murthy V, Laskar SG, Budrukkar  A,  Gupta  T,  et  al.  Hypofractionated,  palliative radiotherapy for advanced head and neck cancer. Radiotherapy and Oncology 2008;89(1):51­6. doi: 10.1016/j.radonc.2008.06.007.

[6] Howlader N, Noone AM, Krapcho M, Miller D, Bishop K, Altekruse SF, et al. SEER Cancer Statistics Review, 1975­2013. Bethesda, MD: National Cancer Institute (2016). Available from: http://seer.cancer.gov/csr/1975_2013. Accessed on 27.12.2022.

[7] Szturz  P  and  Vermorken  JB.  Treatment  of  Elderly  Patients  with  Squamous  Cell  Carcinoma  of  the Head and Neck. Front Oncol 2016; 6:199. doi: 10.3389/fonc.2016.00199.
[8] Hall EJ, Garcia AJ. Time, dose and fractionation in radiotherapy. In: Hall EJ, Garcia AJ eds. Radiobiology for the radiologists. 8th ed. Philadelphia: Lippincott Williams and Wilkins; 2018. p. 417-36.

[9] Carlson DJ, Keall PJ, Loo BW, Chen ZJ, BrownJM. Hypofractionation results in reduced tumor cell killcompared to conventional fractionation for tumors with regions of hypoxia. Int J Radiat Oncol Biol Phys 2011;79(4):1188­95. doi: 10.1016/j.ijrobp.2010.10.007.

[10] Porceddu  SV,  Rosser  B,  Burmeister  BH,  JonescM, Hickeya B, Baumannd K, et al. Hypofrac-tionated radiotherapy for the palliation of advanced head  and  neck  cancer  in  patients  unsuitable  for  curative treatment – "Hypo Trial".  Radiother  Oncol  2007;85(3):456­62. doi: 10.1016/j.radonc.2007.10.020.

[11] Shuryak I, Hall EJ, Brenner DJ. Optimized hy-pofractionation can markedly improve tumor control and decrease late effects for head and neck cancer. Int J Radiation Oncol Biol Phys 2019;104(2):272­8. doi: 10.1016/j.ijrobp.2019.02.025.

[12] Lacas  B,  Carmel  A,  Landais  C,  Wong  SJ,  LicitraL,  Tobias  JS,  et  al.  Meta-analysis  of  chemo-therapy in head and neck cancer (MACH­NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group. Radiother Oncol 2021; 156:281­293. doi: 10.1016/j.radonc.2021.01.013. 

[13] Eisenhauer  EA,  Therasse  P,  Bogaerts  J,  Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumors: Revised RECIST guideline  (version  1.1).  European  J  of  Cancer  2009;45(2):228­47. doi: 10.1016/j.ejca.2008.10.026.

[14] Radiation  Therapy  Oncology  Group.  RTOG  acute and late Radiation Morbidity Scoring criteria. Available at: http://www.rtog.org/ResearchAsso­ciates/  Adverse  Event  Reporting/Acute  and  late  Radiation Morbidity Scoring Criteria.aspx. Accessed on 10.07.2019.

[15] National  Comprehensive  Cancer  Network.  Head and Neck Cancers (Version 1.2022). Available at: https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf. Accessed on 26/12/2022.

[16] Shunyu NB, Syiemlieh J. Prevalence of Head and Neck Cancer in the State of Meghalaya: Hospi­talbased Study. Int J Head and Neck Surg 2013;4(1):1­5.

[17] Al-mamgani A, Tans L, Van rooij PHE, NoeverI, Baatenburg de jong RJ, Levendag PC. Hypofractionated radiotherapy denoted as the “Christie scheme”: An effective  means  of  palliating  patients  with  head  andneck cancers not suitable for curative treatment, Acta Oncologica 2009;48(4):562­70. doi: 10.1080/02841860902740899.

[18] Thomson  DJ,  Palma  D,  Guckenberger  M,  Balermpas  P,  Beitler  J,  Blanchard  P,  et  al.  Practice  recommendations  for  risk-adapted  head  and  neck  cancer  radiation  therapy  during  the  COVID-19  pandemic: an ASTRO­ESTRO consensus statement. Int J Radiat Oncol Biol Phys 2020;107(4):618­27. doi: 10.1016/j.ijrobp.2020.04.016.

[19] Mudgal A, Arya AK, Yadav I, Chaudhary S. Role of  hypofractionated  palliative  radiotherapy  in  patients with stage four head-and-neck squamous cell carcinoma. J Can Res Ther 2019;15:528­32. doi: 10.4103/jcrt.JCRT_116_18.

[20] Nguyen  NT,  Doerwald-Munoz  L,  Zhang  H,  Kim  DH,  Sagar  S,  Wright  JR,  et  al.  0-7-21  hypofrac-tionated palliative radiotherapy: an effective treat­ment for advanced head and neck cancers. Br J Radiol 2015;88(1049): 20140646. doi: 10.1259/bjr.20140646.

[21] Teckie  S,  Benjamin  H,  Rao  S,  Gutiontov  SI,  Yamada Y, Berry SL, et al. High-dose hypofractionated radiotherapy is effective and safe for tumors in the head-­and-­neck. Oral Oncol 2016;60(1):74­80. doi: 10.1016/j.oraloncology.2016.06.016.

[22] Koukourakis MI, Tsoutsou PG, Karpouzis A, Tsiarkatsi  M,  Karapantzos  I,  Daniilidis  V,  et  al.  Radiochemotherapy with cetuximab, cisplatin, and amifostine  for  locally  advanced  head  and  neck  cancer.  A  feasibility  study.  Int  J  Radiat  Oncol  2010;77(1):9­15. doi: 10.1016/j.ijrobp.2009.04.060.

[23] Krstevska V, Stojkovski I, Zafirova­Ivanovska. B.Concurrent radiochemotherapy in locally regionally advanced oropharyngeal squamous cell carcinoma. Analysis of treatment results and prognostic factors. J Radiat Oncol 2012;7(6):78­82. doi: 10.1186/1748­717X­7­78.

[24] Yi J, Huang X, Xu Z, Liu S, Wang X, He X, et al. Phase III randomized trial of preoperative concurrentchemoradiotherapy versus preoperative radio_therapy for patients with locally advanced head and necksquamous  cell  carcinoma.  Oncotarget  2017;  8(27):44842­50. doi: 10.18632/oncotarget.15107.

[25] Bonner  JA,  Harari  PM,  Giralt  J,  Cohen  RB,  JonesCU, Sur RK, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomized, and relation between cetuximab-induced rash and survival. Lancet Oncol 2010;11(1):21­8. doi: 10.1016/S1470­2045(09)70311­0.

[26] Goswami  U,  Banerjee  S,  Dutta  S,  Bera  A.  Treatment outcome and toxicity of hypofractionated radiotherapy with concomitant chemotherapy versus conventional  fractionated  concomitant  chemo-radiation in  locally  advanced  head-and-neck  carci-noma: a comparative study. Asian J Pharm Clin Res 2022;15(7):167­71. doi: 10.22159/ajpcr.2022v15i7.44857. 

[27] Sanghera P, McConkey C, Ho KF, Glaholm J, Hartley A. Hypofractionated accelerated radiotherapy with concurrent chemotherapy for locally advanced squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2007;67(5):1342­51.doi: 10.1016/j.ijrobp.2006.11.015.

[28] Spartacus RK, Dana R, Rastogi K, BhatnagarAR,Daga D, Gupta K. Hypofractionated Radiotherapy for Palliation in Locally Advanced Head and Neck Cancer. Indian J Palliat Care. 2017;23(3):313­16. doi: 10.4103/IJPC.IJPC_9_17. 

[29] Kodaira T, Kagami Y, Shibata T, Shikama N, Nishimura  Y,  Ishikura  S,  et  al.  Results  of  a  multi-institutional, randomized, non-inferiority, phase III trial  of  accelerated  fractionation  versus  standard  fractionation  in  radiation  therapy  for  T1-2N0M0  glottic cancer: Japan Clinical Oncology Group Study (JCOG0701). Ann Oncol. 2018;29(4):992­7. doi: 10.1093/annonc/mdy036.

[30] Lacas B, Bourhis J, Overgaard J, Zhang Q, Grégoire V, Nankivell M, et al. Role of radiotherapy fractionation in head and neck cancers (MARCH): an updated meta­-analysis. Lancet Oncol 2017;18(9):1221–37. doi:10.1016/s1470­2045(17)30458­8.

1492.3. Report of National Cancer Registry Programme (ICMR­NCDIR), Bengaluru, India 2020. Available at: https://www.ncdirinувиdia.org/All_Reports/Report_2020/default.aspx. Accessed on 26.12.2022.4. Mendenhall WM, Werning JW, Pfister DG. Cancer of the head and neck. In: DeVita VT, Hellman S, Rosenberg SA, editors. Cancer: Principals and practice of Oncology. 10th ed. Philadelphia: Wolters Kluwer; 2015. p. 422-24. 5. Aаrwal JP, Nemade B, Murthy V, Laskar SG, Budrukkar A, Gupta T, et al. Hypofractionated, palliative radiotherapy for advanced head and neck cancer. Radiotherapy and Oncology 2008;89(1):51­6. doi: 10.1016/j.radonc.2008.06.007.6. Howlader N, Noone AM, Krapcho M, Miller D, Bishop K, Altekruse SF, et al. SEER Cancer Statistics Review, 1975­2013. Bethesda, MD: National Cancer Institute (2016). Available from: http://seer.cancer.gov/csr/1975_2013. Accessed on 27.12.2022.7. Szturz P and Vermorken JB. Treatment of Elderly Patients with Squamous Cell Carcinoma of the Head and Neck. Front Oncol 2016; 6:199. doi: 10.3389/fonc.2016.00199rly Patients with Squamous Cell Carcinoma of the Head and Neck. Front Oncol 2016; 6:199. doi: 10.3389/fonc.2016.00199